European Medicines Agency recommends authorisation of first-in-class antibiotic for C. difficile

First Page		Document Content
Date: 2013-07-21 06:20:11 Diarrhea Antibiotic-resistant bacteria Clostridium difficile Gram-positive bacteria Gut flora Eli Lilly and Company Fidaxomicin Antibiotic resistance Vancomycin Medicine Microbiology Biology		European Medicines Agency recommends authorisation of first-in-class antibiotic for C. difficile Add to Reading List Source URL: www.ema.europa.eu Download Document from Source Website File Size: 56,90 KB Share Document on Facebook

	Provincial Drug Programs P. O. Box 2000 Charlottetown PE C1A 7N8Toll Free on PEI) Programmes provinciaux de médicaments DocID: 1pGUk - View Document
	NosoVeille – Bulletin de veille Février 2014 DocID: 1fz20 - View Document
	Fidaxomicin DEKLARATION Fidaxomicin (A07AA12) är ett lokalt verkande smalspektrumantibiotikum med baktericid aktivitet mot Clostridium difficile, tillhörande en ny klass av makrocykliska antibakteriella medel. DocID: 1bPNr - View Document
	Senior Hispanic Couple Working In Garden Tidying Pots DocID: 18xVC - View Document
	CHANGE IN PRACTICE The Antimicrobial Stewardship Program (ASP) at University of Miami Hospital is introducing changes to the process of ordering of several antimicrobials. Effective March 12, 2014 the following antimicro DocID: 17CST - View Document